Activity Dates: 12/23/2014 - 12/23/2017
This application-level activity is designed for pharmacists and other healthcare professionals with moderate experience in psychiatric pharmacotherapy. This learning activity would be valuable for residents/fellows, new psychiatric health care professionals, primary care physicians, general practitioners, and general ARNP/PAs.
This course is designed to provide participants with moderate experience a review of evidenced-based, second- and third-line strategies for the treatment of Alzheimer's disease. The goal is for participants to formulate an effective and safe drug therapy plan that can be implemented in a patient with comorbid disease states/drug related problems who has failed first-line therapy. Differentiation between treatment resistance and non-treatment resistance in patients with Alzheimer's disease will also be emphasized. The course will involve review of a recommended reading(s) and analysis of a patient case study with application to an examination. At the conclusion of the course, an evidence-based key will be provided for the case.
You will proceed through the following steps to satisfactorily complete this course:
The course consists of review of a recommended reading(s) and completion of a patient case study. At the conclusion of the course, an evidence-based key will be provided for the case. If the recommended reading is a CPNP product, it is provided. If not, it is the responsibility of the participant to locate the reading.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows Vista and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Monica Mathys, PharmD, CGP, BCPPView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.2 CEUs) of application-based continuing education credit. The ACPE universal program number assigned to this course is 0284-0000-14-083-H01-P (2.0 contact hours).
This educational activity does not contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).
The planners and managers have nothing to disclose related to the content of this CE activity. Editors Benjamin Chavez, PharmD, BCPP, BCACP, and Sarah Grady, PharmD, BCPP, have nothing to disclose related to the content of this CE activity. Editor J. Michael McGuire, PharmD, BCPP, holds stock in Bristol-Myers Squibb and is on the Sunovion Pharmaceutical Inc. Speakers Bureau. Editor Leigh Anne Nelson, PharmD, BCPP, reports research support from Eli Lilly and Otsuka in the area of schizophrenia.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: There may be a discussion of antidepressants and antipsychotics being used for dementia related behavioral disturbances
This activity is sponsored by the College of Psychiatric and Neurologic Pharmacists (CPNP) and supported through educational grants from Eli Lilly, Merck, Otsuka America Pharmaceutical Inc., and Sunovion Pharmaceuticals Inc.